Interfering with chemokines and chemokine receptors as potential new therapeutic strategies
- 16 March 2008
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 18 (3) , 309-325
- https://doi.org/10.1517/13543776.18.3.309
Abstract
Background: Chemokines are a large family of chemotactic proteins that direct migration of leukocytes within the different districts of the body in health and disease. The main function of chemokines is to attract leukocytes to inflammatory sites, but they are also crucially involved in stem cell recruitment, angiogenesis, tumor growth, transplant tolerance, autoimmunity and fibrogenesis. Objective/methods: This is a review of the literature and patents on the therapeutic potential of chemokines. Results/conclusion: This article provides the basis of the biological functions of chemokines and an overview of the potential use of chemokines or chemokine-based approaches for the treatment of HIV infection, rheumatoid arthritis, multiple sclerosis, bronchial asthma and allergic diseases, atherosclerosis, psoriasis, cancer and transplant rejection.Keywords
This publication has 90 references indexed in Scilit:
- Advances in Anti-Inflammatory TherapeuticsExpert Opinion on Investigational Drugs, 2007
- Role of tumor-associated macrophages in tumor progression and invasionCancer and Metastasis Reviews, 2006
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentThe Journal of Experimental Medicine, 2006
- The clinical potential of chemokine receptor antagonistsPharmacology & Therapeutics, 2005
- Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapyBiochemical and Biophysical Research Communications, 2004
- Presentation of Exogenous Antigens on Major Histocompatibility Complex (MHC) Class I and MHC Class II Molecules Is Differentially Regulated during Dendritic Cell MaturationThe Journal of Experimental Medicine, 2003
- Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2Science, 2002
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- The Role of Chemokine Receptors in Primary, Effector, and Memory Immune ResponsesAnnual Review of Immunology, 2000
- Human Chemokines: An UpdateAnnual Review of Immunology, 1997